HTA237 Cost-Effectiveness Analysis of Ofatumumab for Relapsing Remitting Multiple Sclerosis Treatment in Italy
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.1695
https://www.valueinhealthjournal.com/article/S1098-3015(22)03900-6/fulltext
Section Title :
Section Order :
11247
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03900-6&doi=10.1016/j.jval.2022.09.1695